The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

PURPOSE Tasquinimod is a second‐generation orally active quinoline‐3‐carboxamide analog with enhanced potency against prostate cancer via its anti‐angiogenic activity. It is presently undergoing clinical trials. Androgen ablation and taxanes are standard therapies for metastatic prostate cancer. This raises the issue of whether combining tasquinimod with either of these approaches enhances therapeutic efficacy. EXPERIMENTAL DESIGN The tumor growth of a series of human prostate cancer xenografts (CWR‐22Rv1, CWR‐22R‐H, LAPC‐4, LNCaP, PC‐3 and DU‐145) in male nude mice given nothing versus tasquinimod alone or in combination with androgen ablation or with androgen ablation plus taxotere were evaluated as model systems to resolve these issues. RESULTS These studies documented that daily oral treatment with tasquinimod consistently, statistically (P